

7930 Arjons Drive, Suite B San Diego, CA 92126, USA Phone: 1 (858) 265-6446 Fax: 1 (800) 380-4198

Email: orders@gentarget.com

Validated Knockdown human P53 shRNA Lentivirus

| Cat# | Product Name | Amounts |
|---|--|---|
| LVP343-GB; LVP343-GB-PBS; | Lentiviral particles, shRNA (h P53)-(GFP-Bsd) | 1 x10 ⁷ IFU/ml x 200ul |
| LVP343-GP; LVP343-GP-PBS; | Lentiviral particles, shRNA (h P53)-(GFP-Puro) | Or |
| LVP343-RB; LVP343-RB-PBS; | Lentiviral particles, shRNA (h P53)-(RFP-Bsd) | 5 x10 ⁷ IFU/ml x 200ul in PBS |
| LVP343-RP; LVP343-RP-PBS; | Lentiviral particles, shRNA (h P53)-(RFP-Puro) | |
| Validated human P53 shRNA sequence: GTAATCTACTGGGACGGAACA | | |

Storage: <-70 °C, avoid repeat freeze/thaw cycles. Stable for 6 months.

Product Introduction:

GenTarget's lentivector system is Human Immunodeficiency Virus-1 (HIV) based plasmids for gene expression and knockdown. The lentivectors are used to generate lentiviral particles (lentivirus) that can be transduced into almost all kinds of mammalian cells, including stem cells, primary cells, and non-dividing cells both *in vivo* and *in vitro*. Lentiviral Particles stably integrate into the transduced cells' genome for long term expression, making it a great gene transfer agent.

RNA interference (RNAi) technology is a powerful tool for loss-of-function (knockdown/silencing) research in mammalian cells. Originally observed to inhibit gene expression *in vivo* through short double-stranded RNAs, RNAi works through a series of enzymatic reactions mediated by short RNAs having sequences complementary to those of the silenced target. These reactions result in target mRNA degradation or translational repression.

RNAi knockdown can be introduced by short synthetic double-strand RNA (siRNA) or by vector-expressed stem-hairpin RNA (shRNA) which is further processed by Dicer enzyme to produce double-strand short RNAs. Chemically synthesized double stranded RNA (siRNA) has a transient silencing effect only; in contrast, selection of clones for stable vector-expression of RNAi can provide long term silencing.




7930 Arjons Drive, Suite B San Diego, CA 92126, USA Phone: 1 (858) 265-6446 Fax: 1 (800) 380-4198

Email: orders@gentarget.com

One Cell Immortalization method is to repress the genes that control cell cycle such as such as retinoblastoma (Rb) and p53 genes (the tumor suppressor proteins). Therefore, knockdown human P53 lentivirus is used for cell immortalization for a wide variety of cell types.

GenTarget's shRNA Lentivectors:

GenTarget offers the shRNA Lentivirus that knockdown human P53 gene. These pre-made knockdown lentivirus are validated with greater than 75% knockdown level (80% to 97% depends upon cell types). Each P53 shRNA lentivirus contains a **Fluorescent-Antibiotic fusion dual marker** so you can either select the transduced cells by antibiotic killing or sort them via Flow Cytometer. Those products are available in four different dual markers versions as: **GFP-Blasticidin, GFP-Puromycin, RFP-Blasticidin and RFP-Puromycin**. The P53 target specific shRNA is expressed under the human H1 promoter. The fusion dual marker is expressed under RSV promoter. See shRNA lentivector core structure scheme below.



Validated shRNA knockdown:

The validated shRNA knockdown contain a human P53 specific shRNA hairpin insert that demonstrates greater than 75-95% knockdown level depends upon cell types. Knockdown validation was measured via a reporter assay where the specific target was fusioned with a lacZ or luciferase reporter; the knockdown levels were reflected by the decreases of lacZ or luciferase activity. All validated shRNA are guaranteed greater than 75% knockdown level for human P53 endogenous gene.

The premade shRNA lentiviral particles are produced by co-transfection of shRNA lentivector and packaging plasmid into 293T cells. The VSV-G pseudotyped lentiviral particles are provided in 200ul aliquots in DMEM medium, or in PBS solution. For more details about premade particles, please see FAQs for pre-made lentiviral particles (.pdf).



7930 Arjons Drive, Suite B San Diego, CA 92126, USA Phone: 1 (858) 265-6446 Fax: 1 (800) 380-4198

Email: orders@gentarget.com

Simply add the premade shRNA lentivirus into your cell culture, 3 days later, the transduced cells can be selected via antibiotic or via GFP /RFP fluorescent cell sorting, to generate target knockdown cell line. A designed negative control sequence is cloned in the same shRNA lentivector backbone The shRNA-control virus (**shRNA-Ctr**) serves as non-specific knockdown controls for lentivirus treatment.

Key features:

- High shRNA expression level and validated knockdown
- Safe to use: self-inactivation prevents replication of the viron
- **Dual selection**: transduced cells can be sorted via fluorescence or selected for resistance to puromycin or blasticidin
- Easy to use: directly add into cultured cells. There is no need for lipids or transfection reagents. Simply add 50 µl into your cell culture in a 24-well plate. (Note: depending upon your specific needs, you may transduce at different MOIs for different levels of expression.)

Transduction Protocols:

Note: Pre-made lentivirus is provided ready to use, so it can be simply added into your cell culture; the amount of virus to add depends on cell type. For quick transduction, add 50 µl of virus into each well of 24-well-plate where cell density is 50% to 75%. After 72 hours (no need to change medium), visualize positive transduction rate by fluorescence microscopy. For stable cell line generation, pass cells into medium containing antibiotic or perform fluorescence cell sorting followed by antibiotic selection.

Day 0:

Seed cells in complete medium at the appropriate density and incubate overnight.

Note: at the time of transduction, cells should be 50%-75% confluent. For example, seed HeLa cells at $0.5 \times 10^5/\text{ml} \times 0.5\text{ml}$ in a well of a 24-well plate.

Day 1:

- Thaw the pre-made lentiviral stock at room temperature and add the appropriate amount of virus stock to obtain the desired MOI.
- Return cells to 37°C, CO₂ incubator.



7930 Arjons Drive, Suite B San Diego, CA 92126, USA Phone: 1 (858) 265-6446 Fax: 1 (800) 380-4198

Email: orders@gentarget.com

Note: Try to avoid freezing and thawing. If you do not use all of the virus at one time, you may re-freeze the virus at -80 $^{\circ}$ C for future use; virus titer will decrease by ~10% for each freeze/thaw cycle.

Day 3:

At ~72hr after transduction, check the transduction rate by fluorescence microscopy or calculate the exact transduction rate by flow cytometry (FACS or Guava). Then, measure the knockdown level by Q-RT-PCR or WB.

Day 3 (optional):

Sort transduced cells by FACS, and select for antibiotic resistance. A pilot experiment should be done to determine the antibiotic's kill curve for your specific cell line (refer to the pertinent literature on generation of stable cell lines). Then, measure the knockdown level by Q-RT-PCR or WB on the selected cells.

Note: Filter wavelength settings:

GFP filter: ~Ex450-490 ~Em525; RFP filter: ~Ex545 ~Em620;

Safety Precaution:

Gentarget lentiviral particles adapts must advanced lentiviral safety features (using the third generation vectors with self-inactivation SIN-3UTR), and the premade lentivirus is replication incompetent. However, please use extra caution when using lentiviral particles. Use the lentiviral particles in Bio-safety II cabinet. Ware glove all the time at handling Lentiviral particles! Please refer CDC and NIH's guidelines for more details regarding to safety issues.

References:

- 1. Molecular Therapy (2003) 7, 460-466; doi: 10.1016/S1525-0016(03)00024-8
- 2. Annu Rev Microbiol. 1994;48:345-69.
- 3. Microbiol Mol Biol Rev. 2005 Jun;69(2):326-56.
- 4. NIH Guidelines for Biosafety Considerations for Research with Lentiviral Vectors. (Link).
- 5. CDC quidelines for Lab Biosafety levels (Link).

Warranty:

This product is for research use only. It is warranted to meet its quality as described when used in accordance with its instructions. GenTarget disclaims any implied warranty of this product for particular application. In no event shall GenTarget be liable for any incidental or consequential damages in connection with the products. GenTarget's sole remedy for breach of this warranty should be, at GenTarget's option, to replace the products.



7930 Arjons Drive, Suite B San Diego, CA 92126, USA Phone: 1 (858) 265-6446

Fax: 1 (800) 380-4198 Email: orders@gentarget.com

<u>Attachment:</u> GenTarget's pre-made lentivirus product categories.

| Product | Product Description | |
|--|---|--|
| Category | (please click into each category's page) | |
| <u>Pathway</u> | Repoter Lentivirus for all kinds of pathway screening | |
| Reporter | assays | |
| Cell | Lentivirus for cell immortalization: Large T-antigen, | |
| Immortalization | hTERT, EBNA1/EBNA2, HpV16-E6/E7, Adenovial E1A, Kras_G12V, HOXA9, et al. | |
| | Lentivirus products for immuno therapy research: CAR | |
| Transcript On solo av | and TCR; Assay Cell Lines for T-cell targeted killing | |
| ImmunoOncology Research | assay and other cell-based assays; over-expression lentivirus products for the immune response targets; | |
| Research | Cell surface antigens (CDs); immune checkpoint / | |
| | Receptors; CRISPR gene Repair and knock-IN lentivirus; | |
| | CRISPR knockout lentivirus; | |
| CAR-T, TCR | CARs Lentivirus: Anti-CD19 /CD20 /CD22 /BCMA | |
| <u>Lentivirus</u> | /hHER2 /HLA-A2 /TGFβ; TCRs : MART-1/ NY-ESO1/ | |
| | CD1d-a-GalCer/ TRaV3-F2A-TRβV5-6; | |
| CRISPR Gene | Preamde lentivirus express humanzied wild-type Cas9 | |
| <u>Editing</u> | endonuclease, the dCas9 , gRNAs, CRISPR gene editing | |
| Epigenomic: | research "dCas9-Protein" fusion Lentivirus for epigenomic | |
| CRISPRi and | modification, resulted in CRISPR interference (CRISPRi) | |
| CRISPRa | or activation (CRISPRa). | |
| | a set of reporter lentiviruses to express a luminescence | |
| <u>Cell-Specific</u> | or fluorescent reporter (firefly Luciferase, Renilla | |
| Reporter | luciferase, RFP or GFP fluorescent marker) under a | |
| T. C. 11 | tissue specific promoter | |
| <u>Infectious</u> | Llentivirus that express all kinds of infectious antigens | |
| <u>Antigens</u> | with C-term 6His-tag. | |
| <u>Virus Like</u> | Lentiviral Like Particles, pseudo-typed with a different | |
| Particles (VLP) | envelope proteins. | |
| Non-integrating | Integration Defective Lentivirus, express different | |
| LV | targets for transient expression without the unwanted | |
| <u>shRNA</u> | insertional mutagenesis. Knockdown verifeid and customized shRNA lentivirus for | |
| Knockdown | target knockdown, | |
| - Italia Cita Cita Cita Cita Cita Cita Cita Ci | tal got knockdown/ | |



7930 Arjons Drive, Suite B San Diego, CA 92126, USA Phone: 1 (858) 265-6446 Fax: 1 (800) 380-4198

Email: orders@gentarget.com

| Product | Product Description | |
|------------------------|---|--|
| Category | (please click into each category's page) | |
| microRNA | Premade lentivirus expression human or mouse | |
| <u>lentivirus</u> | precursor miRNA. And anti-miRNA lentivector and | |
| | virus for human and mouse miRNA. | |
| <u>Anti-miNA</u> | Pre-made lentivirus expression a specific anti-miRNA | |
| <u>lentivirus</u> | cassette. | |
| Human and | Premade lentivirus expressin a human, mouse or rat | |
| mouse ORFs | gene with RFP-Blastididin fusion dual markers. | |
| <u>Luciferase</u> | Premade lentivirus for all kinds of luciferase protein | |
| <u>expression</u> | expression: firefly and Renilla, Red-Luc and more, | |
| | with different antibiotic selection markers. | |
| <u>Fluorescent</u> | Lentivirus express all commonly used fluorescent | |
| <u>Markers</u> | proteins: GFP, RFP, CFP, BFP YFP, niRFP, unstable GFP | |
| | and others. | |
| Luminescent | Lentivirus express Nano-Latern as Bio-probes for in vivo | |
| <u>Imaging</u> | imaging of sub-cellular structural organization and | |
| | dynamic processes in living cells and organisms | |
| Sub-cellular | Lentivirus contain a well-defined organelle targeting | |
| <u>Imaging</u> | signal fusioned to a fluorescent protein, great tools for | |
| | live-cell imaging and for dynamic investigation of sub- | |
| Cytockoloton | cellular signal pathways. | |
| <u>Cytoskeleton</u> | A fluorescent marker (GFP, RFP or CFP) fusion with a cellular structure protein, provides a convenient tool for | |
| Imaging | visualization of cytoskeletal structure | |
| Unstable GFP | Lentivirus express the the destabilized GFP (uGFP) which | |
| OTISCOSIC CIT | provides fast turnover responses in signal pathway | |
| | assay and in knockdown / knockout detection | |
| near-infrared RFP | The near-infrared Red fluorescent (niRFP) expression | |
| | Lentiviurs provides the whole-body images with better | |
| | contrast and brighter images | |
| Fluorescent-ORF | Pre-made lentivirus expression a "GFP/RFP/CFP-ORF" | |
| <u>fusion</u> | fusion target. | |
| | Premade lentivirus for expressing nuclear permeant | |
| <u>CRE recombinase</u> | CRE recombinase with different flurescent and antibiotic | |
| | markers. | |
| CRE, Flp | Lentivirus expressing "LoxP-GFP-Stop-LoxP-RFP" or | |
| <u>ColorSwtich</u> | "FRT-GFP-Stop-FRT-RFP" cassette, used to monitor the | |
| | CRE or Flp recombination event in vivo. | |



7930 Arjons Drive, Suite B San Diego, CA 92126, USA Phone: 1 (858) 265-6446 Fax: 1 (800) 380-4198

Email: orders@gentarget.com

| Product | Product Description | |
|---|---|--|
| Category | (please click into each category's page) | |
| SEAP Reporter | lentivirus expressing SEAP under different promoters (TetCMV, EF1a, CAG, Ubc, mPGK, Actin-beta or a signal pathway responsive promoter), | |
| TetR Repressor | Premade lentivirus expressin TetR (tetracycline regulator) protein, the repressor protein for the inducible expression system. | |
| rtTA Expression | rtTA binds to the tetracycline operator element (TetO) in the presence of doxycycline (Dox). Used for Tet-On /OFF inducible system. | |
| <u>iPS factors</u> | Premde lentivirus for human and mouse iPS (Myc, NANOG, OCT4, SOX2, FLF4) factors with different fluorescent and antibitoic markers | |
| LacZ expression | Express different full length β- galactosidase (lacZ) with different selection markers | |
| Negative control lentiviruses | Premade negative control lentivirus with different markers: serves as the negative control of lentivurs treatment, for validation of the specificity of any lentivirus target expression effects. | |
| Other Enzyme expression | Ready-to-use lentivirus, expressing a specific enzymes with different selection markers. | |
| <u>Ultra titer</u> <u>lentivirus</u> | Ultra-titer lentivirus used for the hard-to-transduced cells and for in vivo manipulation of sperm cells, or stem cells. | |